Hologic's total breast tomosynthesis solution and other leading-edge products to be featured at the European Congress of Radiology in Vienna
BEDFORD, Mass., March 3, 2014 -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, will showcase its extensive portfolio of innovative products for breast cancer screening and diagnosis, breast biopsy, osteoporosis risk assessment, and extremity imaging at the annual meeting of the European Society of Radiology, in Vienna, Austria March 6th through 10th. The European Congress of Radiology (ECR), the largest medical imaging meeting in Europe, annually attracts over 20,000 participants representing the medical specialty of radiology throughout Europe and many other countries of the world.
"ECR will be a particularly exciting time for us to showcase our total breast tomosynthesis solution to the radiology world," said David Harding, Hologic's Group Senior Vice President and General Manager, Women's Health. "The growing number of peer-reviewed clinical publications confirming the efficacy of our C-View software as a lower-dose alternative for tomosynthesis exams, coupled with the strong performance of our tomosynthesis biopsy option for the Affirm breast biopsy guidance system, strengthens our position as the only provider of a complete 3D package for screening, diagnostic and interventional applications. This meeting provides an excellent opportunity to highlight why our tomosynthesis technology is gaining widespread acceptance based on its ability to detect invasive breast cancers earlier and decrease anxiety-provoking recalls while offering a versatile platform for advanced applications."
To further highlight the advances in its breast tomosynthesis technology, Hologic is offering three special tomosynthesis-related events at ECR:
-- A special ECR Satellite Symposium, "Breast Tomosynthesis: Evolution and
Adoption Across Europe," on Saturday, March 8 from 2:00 to 3:30 p.m. in
the Austria Center Vienna, Room C. The symposium will feature speakers
from various countries throughout Europe, including: Fiona Gilbert, Cambridge, United Kingdom - The use of breast tomosynthesis in the screening assessment in the UK. Melcior Sentis, Sabadell, Spain - Using breast tomosynthesis with C-View 2D images and tomosynthesis guided biopsy: our experience in Spain. Francesca Caumo, Verona, Italy - Diagnostic and interventional use of breast tomosynthesis: our experience in Italy. Martin Sonnenschein, Bern, Switzerland - The use of breast tomosynthesis with C-View images and tomosynthesis guided biopsy in daily practice: our experience in Switzerland. Per Skaane, Oslo, Norway - Incorporating breast tomosynthesis in a population-based screening program: our experience in Oslo.
-- Eight 75-minute breast tomosynthesis education sessions from March 7th
through the 9th. Each session includes hands-on experience reading breast
tomosynthesis images in combination with conventional and generated
(C-View) 2D images.
-- Fourteen breast biopsy guided by tomosynthesis training workshops from
March 7th through the 9th. Each workshop will include an overview of the
first clinical experiences with vacuum-assisted breast biopsies guided by
tomosynthesis prior to a demonstration of a phantom procedure. There will
be time at the end of each session for hands-on training. For additional information and registration information, please email Tomoinfo@hologic.com.
Other Leading-edge Products on Display:
Horizon Bone Densitometry (DXA) System. Shown for the first time in Europe, Hologic's Horizon DXA system provides a single platform for osteoporosis and obesity assessment, visualization of abdominal aortic calcifications and an innovative new feature enabling atypical femur fracture assessment.
Selenia Dimensions Avia Package. A cost-effective option for customers seeking a 2D screening only or 2D screening and diagnostic solution, this package provides an upgrade pathway for interventional and tomosynthesis capabilities.
Fluoroscan InSight-FD Mini C-arm. Featuring flat panel detector technology, this system is designed specifically for orthopedic and extremity surgeons and offers a thin profile and improved workspace access with enhanced ease of positioning.
Breast Biopsy Systems. Hologic's Eviva and ATEC breast biopsy systems are designed to conduct minimally invasive biopsy procedures under stereotactic, ultrasound, or MRI guidance.
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company operates four core business units focused on breast health, diagnostics, GYN surgical, and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.
Hologic, Affirm, ATEC, C-View, Dimensions, Eviva, Fluoroscan, Horizon and Selenia are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Forward-looking Statement Disclaimer:
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.